Fairway Wealth LLC Has $841,000 Stock Position in Johnson & Johnson $JNJ

Fairway Wealth LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2,916.7% in the 1st quarter, Holdings Channel reports. The firm owned 3,439 shares of the company’s stock after buying an additional 3,325 shares during the quarter. Fairway Wealth LLC’s holdings in Johnson & Johnson were worth $841,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Greenberg Financial Group bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $954,000. World Investment Advisors raised its position in shares of Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares during the period. JT Stratford LLC lifted its stake in shares of Johnson & Johnson by 7.6% in the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock worth $11,047,000 after buying an additional 4,216 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock worth $17,738,000 after buying an additional 8,533 shares during the last quarter. Finally, Benchmark Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $554,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $253.76 on Thursday. The firm has a market capitalization of $610.86 billion, a PE ratio of 29.34, a PEG ratio of 2.49 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1-year low of $154.21 and a 1-year high of $259.90. The business’s 50 day moving average is $232.26 and its 200-day moving average is $230.68.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is strengthening its cancer franchise with positive European regulatory news for Tecvayli in combination with Darzalex SC, plus a planned acquisition of Firefly Bio to expand its oncology pipeline. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Positive Sentiment: Management reiterated that J&J is prioritizing cancer and neuroscience rather than entering the obesity drug market, which signals a disciplined capital-allocation strategy and a clearer long-term growth plan. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: J&J is being featured by multiple outlets as a top dividend and income stock, and technical commentary says the shares are breaking out past a buy point, which may be encouraging momentum-oriented investors. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Analysts are focusing on upcoming Q2 Innovative Medicine results, with Stelara biosimilar pressure expected to offset some growth from newer therapies; investors may be waiting for earnings confirmation before pushing the stock higher. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Recent market coverage notes that J&J has already had a strong one-year rally, so some investors are now weighing whether the valuation still offers upside from here. Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Bank of America upped their price target on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Johnson Rice set a $270.00 price target on Johnson & Johnson in a research report on Friday, June 26th. Citigroup lifted their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.70.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.